Vascular Research Training

描述（由申请人提供）：这是耶鲁大学血管研究博士后T32的第二个竞争性更新申请。迄今为止，在完成培训的研究员中，86%获得了学术教职，86%进入了独立的科学生涯，这是项目成功的有力指标。持续的目标是为高素质的医生（医学博士）提供实验室和转化研究培训。和医学博士。/博士）和博士博士后研究员在血管生物学，在准备职业生涯作为独立的研究人员在血管生物学和医学相关学科。学员的选择将基于对血管生物学的承诺和强大的先前研究经验或潜力。将鼓励临床和基础科学部门的申请，全国范围内的竞争为7年一次。少数民族申请人将被特别邀请。培训将以导师为基础，还包括咨询委员会和教学课程。培训的最短时间为2年，大多数研究员将留在该计划3年。心血管医学部和耶鲁大学的血管生物学和治疗学跨学科计划将是该计划的基础。这个培训项目的一个关键资产是耶鲁大学在血管生物学方面的跨学科优势。参与教师的部门隶属关系包括心血管医学，肺和重症监护医学，免疫生物学，药理学，分子细胞和发育生物学，病理学，遗传学，生物工程，生理学，流行病学和公共卫生，以及心胸外科。这证明了耶鲁大学强大的血管生物学实验室的广泛性和该计划的机构性质。教师的选择是基于令人印象深刻的指导历史，正在进行的血管研究生产力，强大的校外支持和承诺，以作为该计划内的导师。研究机会的例子包括：（1）白细胞-内皮细胞相互作用的分子决定因素和后果;（2）在动物模型中利用核成像和MR成像对血管生成和血管重塑进行分子成像;（3）绘制和鉴定有助于血管疾病发展的基因（动静脉畸形，冠状动脉疾病）;（4）血管生物材料的工程化，以及植入后愈合反应的分子决定因素;和（5）产生用于临床试验的血管生成基因调节剂。这代表了广泛的疾病相关血管研究，具有关键的翻译组成部分。学员的进度将由每位导师、学员咨询委员会和项目总监监督。这是期望，我们将培养未来的国家和国际领导人在血管研究。心血管疾病是美国人死亡的主要原因，也是世界范围内死亡的主要原因。该计划将为来自多个学科的个人提供重要的机会，最终导致高影响力的努力，减少心血管疾病的发病率，并改善心血管疾病的预后。

DESCRIPTION (provided by applicant): This is the second competing renewal application for Yale University's Vascular Research Postdoctoral T32. Of fellows who have completed training to date, 86% have obtained academic faculty positions, and 86% have entered independent scientific careers, strong indicators of program success. The continued goal is to provide laboratory and translational research training for highly qualified physician (M.D. and M.D. /Ph.D.) and Ph.D. postdoctoral fellows in vascular biology, in preparation for careers as independent investigators in blood vessel biology- and medicine-related disciplines. Selection of trainees will be based on a commitment to vascular biology and strong prior research experience or potential of same. Applications will be encouraged from clinical and basic science departments, with a nationwide competition for 7 yearly slots. Minority applicants will be specifically solicited. The training will be mentor-based, also including advisory committees and didactic courses. The minimum duration of training will be 2 years, with the majority of fellows remaining in the program for 3 years. The Cardiovascular Medicine Division and Yale's Interdisciplinary Program in Vascular Biology and Therapeutics will be the foundations for the program. A key asset to this training program is Yale's interdisciplinary strength in vascular biology. Departmental affiliations for participating faculty include Cardiovascular Medicine, Pulmonary and Critical Care Medicine, Immunobiology, Pharmacology, Molecular Cellular and Developmental Biology, Pathology, Genetics, Bioengineering, Physiology, Epidemiology and Public Health, and Cardiothoracic Surgery. This is a testimony to the wide spectrum of strong vascular biology laboratories at Yale and the program's institutional nature. The faculty was chosen based on impressive histories of mentorship, ongoing vascular research productivity, strong extramural support and commitment to serve as mentors within the program. Examples of research opportunities include: (1) molecular determinants and consequences of leukocyte-endothelial cell interactions; (2) molecular imaging of angiogenesis and vascular remodeling utilizing nuclear and MR imaging in animal models; (3) mapping and identification of genes that contribute to the development of vascular disease (arterio-venous malformation, coronary artery disease) in humans; (4) engineering of vascular biomaterials, and molecular determinants of healing responses post-implantation; and (5) generation of angiogenic gene regulators for use in clinical trials. This represents a wide range of disease-related vascular research, with key translational components. Trainee progress will be monitored by each mentor, the trainee's advisory committee and the Program Director. It is the expectation that we will train future national and international leaders in vascular research. Cardiovascular disease is the leading cause of death in the U.S., and a major cause of mortality world-wide. This program will provide important opportunities for individuals from multiple disciplines to eventually lead high impact efforts at reducing the incidence of, and improving outcomes in, cardiovascular disease.